Claims
- 1. A transgenic mouse comprising a disruption in a HSPC150-like gene.
- 2. A transgenic mouse comprising a disruption in a HSPC150-like gene, wherein there is no native expression of endogenous HSPC150-like gene.
- 3. The transgenic mouse of claim 2, wherein the disruption is heterozygous.
- 4. The transgenic mouse of claim 2, wherein the disruption is homozygous.
- 5. The transgenic mouse of claim 4, wherein the transgenic mouse exhibits a phenotypic abnormality, wherein the abnormality is selected from the group consisting of: a genitourinary system abnormality, a reproductive system abnormality, a neurological abnormality, a lipoprotein abnormality and a body composition abnormality.
- 6. The transgenic mouse of claim 5, wherein the genitourinary system abnormality or the reproductive abnormality is characterized by smaller genitalia size.
- 7. The transgenic mouse of claim 5, wherein the genitourinary system abnormality or the reproductive abnormality is characterized by lower genitalia weight.
- 8. The transgenic mouse of claim 5, wherein the genitourinary system abnormality or the reproductive abnormality is characterized by hypospermatogenesis.
- 9. The transgenic mouse of claim 5, wherein the genitourinary system abnormality or the reproductive abnormality is characterized by degenerate seminiferous tubules.
- 10. The transgenic mouse of claim 5, wherein the neurological abnormality is characterized by decreased motor coordination.
- 11. The transgenic mouse of claim 5, wherein the lipoprotein abnormality is characterized by an elevated level of high density lipoprotein.
- 12. The transgenic mouse of claim 5, wherein the body composition abnormality is characterized by an elevated amount of body fat.
- 13. A method of producing a transgenic mouse comprising a disruption in a HSPC150-like gene, the method comprising:
(a) providing a murine stem cell comprising a disruption in a HSPC150-like gene; and (b) introducing the murine stem cell into a pseudopregnant mouse, wherein the pseudopregnant mouse gives birth to a transgenic mouse.
- 14. The transgenic mouse produced by the method of claim 13.
- 15. A targeting construct comprising:
(a) a first polynucleotide sequence homologous to at least a first portion of a HSPC150-like gene; (b) a second polynucleotide sequence homologous to at least a second portion of a HSPC150-like gene; and (c) a selectable marker.
- 16. A cell comprising a disruption in a HSPC150-like gene, the disruption produced using the targeting construct of claim 15.
- 17. A cell derived from the transgenic mouse of claim 2.
- 18. A cell comprising a disruption in a HSPC150-like gene.
- 19. The cell of claim 18, wherein the cell is a stem cell.
- 20. The cell of claim 19, wherein the stem cell is an embryonic stem cell.
- 21. The cell of claim 20, wherein the embryonic stem cell is a murine cell.
- 22. A method of identifying an agent that modulates a phenotype selected from the group consisting of a genitourinary system abnormality, a reproductive system abnormality, a neurological abnormality, a lipoprotein abnormality and a body composition abnormality, the method comprising:
(a) contacting a test agent with HSPC150-like gene product; and (b) determining whether the agent modulates HSPC150-like gene product.
- 23. A method of identifying an agent that modulates a phenotype selected from the group consisting of a genitourinary system abnormality, a reproductive system abnormality, a neurological abnormality, a lipoprotein abnormality and a body composition abnormality, the method comprising:
(a) administering a test agent to an animal exhibiting a phenotype selected from the group consisting of a genitourinary system abnormality, a reproductive system abnormality, a neurological abnormality, a lipoprotein abnormality and a body composition abnormality; and (b) determining whether the agent modulates the phenotype.
- 24. A method of evaluating a potential therapeutic agent capable of affecting a condition associated with a mutation in a HSPC150-like gene, the method comprising:
(a) administering the potential therapeutic agent to a transgenic mouse comprising a disruption in a HSPC150-like gene; and (b) evaluating the effects of the agent on the transgenic mouse.
- 25. A method of evaluating a potential therapeutic agent capable of affecting a condition associated with a mutation in a HSPC150-like gene, the method comprising:
(a) contacting the potential therapeutic agent with HSPC150-like gene product; (b) evaluating the effects of the agent on the HSPC150-like gene product.
- 26. A method of determining whether an agent modulates HSPC150-like gene product, the method comprising:
(a) providing a first preparation derived from the mouse of claim 2;(b) providing a second preparation derived from a wild-type mouse; (c) contacting a test agent with the first and second preparations; and (d) determining whether the agent modulates the first and second preparations, wherein modulation of the second preparation but not the first preparation indicates that the agent modulates the HSPC150-like gene product.
- 27. A pharmaceutical composition comprising a HSPC150-like gene or HSPC150-like gene product.
- 28. A method of preparing a pharmaceutical composition for a condition associated with a function of HSPC150-like gene product, the method comprising:
(a) identifying a compound that modulates HSPC150-like gene product; (b) synthesizing the identified compound; and (c) incorporating the compound into a pharmaceutical carrier.
- 29. Phenotypic data associated with a transgenic mouse comprising a disruption in a HSPC150-like gene, wherein the phenotypic data is in an electronic database.
RELATED APPLICATIONS
[0001] This application claims priority to U.S. Provisional Application No. 60/301,281, the entire contents of which are incorporated herein by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60301281 |
Jun 2001 |
US |